Sunday Science Testosterone 2026_04_19

Sunday Science: Testosterone Therapy – Risks, Benefits & Longevity Debate Summary by Speaker Dr. Brent Laartz Discusses testosterone decline with age (0.4-2.6%/year, 30-50% by 50-60), low T ( Reviews studies: - Low T associated with 1.5-2.3x higher all-cause, CV, cancer mortality (2010 European Heart Journal cohort; 2011 JCEM meta-analysis). - Frailty mediates 35% of low T mortality risk. - Eunuch/castration studies (Korea, Poland, animals): 10-20% longer lifespan, but pre-puberty vs. late-life low T. - TRT studies: Decreased mortality if levels normalized (2012, 2015 European Heart Journal cohorts); short-term (3 years) benefit; non-normalized TRT no benefit. Notes biases in cohorts (healthy user effect); no RCTs yet. Emphasizes N=1 individualized approach considering personal risks (e.g., prostate/heart disease). Key Points and Decisions **Low Endogenous Testosterone**: Strongly linked to higher mortality (all-cause, CV, cancer); associated with frailty, metabolic issues. **Castration/Eunuch Data**: Suggests lifelong low T may extend life, but not directly comparable to adult TRT. **TRT Evidence**: Cohort studies show mortality reduction with normalized levels (esp. long-term), but short-term CV risks possible; no definitive RCTs. **No Firm Decisions**: Informational only; no endorsements for/against TRT; highlights need for RCTs to resolve controversy. Next Steps **Research**: Await randomized controlled trials (RCTs) for definitive TRT mortality data. **Individuals**: Check testosterone/health markers regularly (yearly+); consult physicians for personalized risks/benefits; prioritize resistance training, healthy lifestyle. **Audience**: Seek professional medical advice; follow show on YouTube, Spotify, Apple Podcasts, social media, goonpro.com.